Blood Biomarker For Identifying Benign Lung Nodules Displays “Excellent” Performance Across Subgroups, Research Shows

Healio (7/25, Hornick) reports, “A blood biomarker used to identify benign vs. malignant pulmonary nodules displayed ‘excellent’ performance regardless of sex, smoking status, screen detection and nodule size, according to a research letter.” Specifically, the biomarker’s negative predictive value “was more than 90% in men and women,” with researchers also observing “high values across smoking status and nodule size subgroups.” Healio adds, “The biomarker, or proteomic integrated classifier (IC), joins together plasma proteins LG3BP and C163A with smoking status, nodule size, edge and location, according to researchers.” The findings were published in the journal CHEST.